![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
LabCorp, a leading global life sciences company that is deeply integrated in guiding patient care, announced that Covance, its drug development business, has deployed the Xcellerate® COVID-19 solution as part of its award-winning Xcellerate platform. Covance has developed a comprehensive approach to reinitiate ongoing research and start up new studies, with a focus on patient safety and study delivery. Designed in conjunction with Covance’s COVID-19 Operational Recovery Team, the Xcellerate® COVID-19 solution offers integrated data collection, actionable views of critical study data, COVID-19 targeted risk management and recovery assessment.
Global clinical research has been disrupted by the COVID-19 pandemic. Specific impacts include studies being halted or paused and enrollment being delayed. Many clinical research sites around the world have restricted all but essential visits except for patient safety, with study monitoring conducted remotely where possible. As healthcare conditions improve globally, research sites are positioned to resume studies.
“In the same way the global scientific and research community has mobilized to battle the COVID-19 pandemic, we must apply the same innovation and rigor to resuming ongoing research,” said Jonathan E. Shough, chief information officer LabCorp’s drug development business. “The Xcellerate COVID-19 solution enables study teams and sponsors to respond to changing facts on the ground with near-real-time, data-driven analytics and consumer-grade visualizations. Our data-driven, real-world approach provides a platform for the safe and rapid restoration of essential research. Patients deserve nothing less.”
The Xcellerate COVID-19 solution reinforces Covance’s tailored research recovery roadmap that combines central oversight and governance with local decision making and site centricity to address the complexity of the pandemic’s impact on research globally. The Covance Operational Recovery Team provides strategic oversight, clear accountability and study support. Powered by Xcellerate, this central team oversees risk review and mitigation plans for each study, including review of timelines, quality measures, endpoint data, vendors, financials and inspection readiness. The roadmap supports adaptive, agile and innovative approaches to maintain continuity, protect patients and preserve critical endpoints. In the longer term, Covance’s comprehensive approach to research recovery is designed to support patients, minimize the number of patients that drop out of studies, prevent missed visits to sites and optimize data integrity.
The Xcellerate COVID-19 solution combines different components of the Xcellerate informatics suite to create a tailored data collection capability, risk assessment tools, centralized monitoring and advanced metrics reporting. Its visualization dashboards provide actionable views of critical study data so that operational teams can make effective decisions, increase efficiency and reduce risk. It comprises:
About LabCorp
LabCorp , an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostics solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11.5 billion in 2019.
